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ABSTRACT
Objectives Endothelial dysfunction may be connected 
to cardiovascular disease (CVD) in systemic lupus 
erythematosus (SLE). Type I interferons (IFNs) are central 
in SLE pathogenesis and are suggested to induce both 
endothelial dysfunction and platelet activation. In this 
study, we investigated the interplay between endothelial 
dysfunction, platelets and type I IFN in SLE.
Methods We enrolled 148 patients with SLE and 79 
sex-matched and age-matched healthy controls (HCs). 
Type I IFN activity was assessed with a reporter cell assay 
and platelet activation by flow cytometry. Endothelial 
dysfunction was assessed using surrogate markers of 
endothelial activation, soluble vascular cell adhesion 
molecule-1 (sVCAM-1) and endothelial microparticles 
(EMPs), and finger plethysmograph to determine Reactive 
Hyperaemia Index (RHI).
Results In patients with SLE, type I IFN activity was 
associated with endothelial activation, measured by high 
sVCAM-1 (OR 1.68, p<0.01) and elevated EMPs (OR 1.40, 
p=0.03). Patients with SLE with high type I IFN activity 
had lower RHI than HCs (OR 2.61, p=0.04), indicating 
endothelial dysfunction. Deposition of complement factors 
on platelets, a measure of platelet activation, was seen 
in patients with endothelial dysfunction. High levels of 
sVCAM-1 were associated with increased deposition of 
C4d (OR 4.57, p<0.01) and C1q (OR 4.10, p=0.04) on 
platelets. High levels of EMPs were associated with C4d 
deposition on platelets (OR 3.64, p=0.03).
Conclusions Endothelial dysfunction was associated 
with activation of platelets and the type I IFN system. We 
suggest that an interplay between the type I IFN system, 
injured endothelium and activated platelets may contribute 
to development of CVD in SLE.
IntROduCtIOn
Systemic lupus erythematosus (SLE) is a 
systemic autoimmune disease that predom-
inately affects women of reproductive age. 
An increased prevalence of cardiovascular 
disease (CVD) in SLE is well described. To 
some extent this increase may be explained 
by traditional CVD risk factors, such as 
smoking, dyslipidaemia and diabetes,1–3 and 
SLE disease-related risk factors, including 
steroid treatment, renal impairment and pres-
ence of antiphospholipid antibodies.4 Type I 
Interferons (IFNs) have been suggested to 
be linked to CVD in SLE, as those cytokines 
may mediate imbalance between endothelial 
destruction and repair, leading to endothelial 
dysfunction, an early stage in atherosclerosis 
development.5 In addition to their role in 
CVD and SLE pathogenesis,6 7 platelets have 
an impact on endothelial function.8 The 
aim of this study was to take both type I IFN 
activity and platelet activation into account 
when investigating endothelial dysfunction in 
SLE.
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Key messages
What is already known about this subject?
 ► Patients with systemic lupus erythematosus (SLE) 
have increased risk for cardiovascular disease 
(CVD) and both activation of type I interferons 
(IFNs) and platelets have been implicated in this 
process.
 ► Endothelial dysfunction, an early step in the 
development of atherosclerosis, can be assessed 
by non-invasive techniques as well as by surrogate 
markers, such as soluble vascular cell adhesion 
molecule-1 and endothelial microparticles.
What does this study add?
 ► Patients with SLE may have elevated type I IFN 
activation leading to impaired endothelial function 
including patients with low disease activity.
 ► Patients with SLE and endothelial dysfunction have 
activated platelets, which may contribute to an 
elevated risk of CVD.
How might this impact on clinical practice?
 ► Analysing type I IFN signature, endothelial 
function and platelet activation may add valuable 
information when evaluating cardiovascular risk in 
the individual patient with SLE.
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Endothelial dysfunction is a state of impaired endothe-
lial dependent vasodilatation that also consists of endo-
thelial activation, a proinflammatory state with decreased 
endothelial anticoagulant ability.9 10 Several methods may 
be used to assess endothelial dysfunction. Serum levels of 
endothelial derived markers, such as soluble vascular cell 
adhesion molecule-1 (sVCAM-1), is elevated as a conse-
quence of endothelial activation and dysfunction.11 12 
Furthermore, endothelial microparticles (EMPs), subcel-
lular vesicular fragments that shed from endothelial cells 
in response to certain stimuli,13 have been reported to 
correlate with endothelial dysfunction14 15 and endothe-
lial damage.13 Non-invasive techniques to assess endothe-
lial dysfunction have been developed, with flow mediated 
dilatation (FMD) measurement of the brachial artery 
considered as the gold standard.9 However, the method 
is complex and operator-dependent. Abnormal pulse 
wave amplitude (PWA) in peripheral arteries as a marker 
of atherosclerosis and predictor of cardiovascular events 
may be used as an alternative.16 17Peripheral artery tonom-
etry (PAT) using a device called EndoPAT has been devel-
oped to measure PWA in finger arteries and is an easy, 
investigator independent, method to assess endothelial 
dysfunction. A linear relationship between endothelial 
dysfunction measured with FMD and EndoPAT has been 
demonstrated previously.18
Type I IFNs are key cytokines in the pathogenesis of SLE 
with a number of regulatory effects on both innate and 
adaptive immunity19 and have been suggested to mediate 
increased endothelial progenitor cell (EPC) apoptosis 
and the differentiation of circulating angiogenic cells 
(CACs) to non-angiogenic cells. This imbalance between 
vascular damage and repair may cause endothelial 
dysfunction in SLE. In addition, type I IFNs affect the 
capacity of EPC/CAC to produce proangiogenic mole-
cules which can be restored by blocking type I IFNs in 
vitro.5 In SLE, type I IFNs have been demonstrated to 
exert their effects on EPC/CACs through downregu-
lation of the proangiogenic interleukin (IL)−1 signal-
ling pathways and by affecting the inflammasome and 
promoting IL-18 activation as well as IL-1β repression.20 21 
Elevated levels of type I IFNs correlate with endothelial 
dysfunction and EPC decrease in SLE.22 In line with this 
observation, an association between increased serum 
type I IFN activity and markers of subclinical atheroscle-
rosis in patients with SLE has been described, suggesting 
a role of type I IFNs in atherosclerosis development.23
Previous studies have established that platelets are of 
importance in the development of CVD.6 In recent years, 
the role of platelets in the pathogenesis of SLE with a 
possible link between the type I IFN system and platelet 
function has been investigated.7 24 Platelets also play a role 
in endothelial activation and function, as they attract and 
promote EPCs' adhesion to the injured vascular wall.8 25 
Therefore, the aim of this study was to investigate platelet 
activation in patients with SLE in relation to endothelial 
activation and type I IFN activity, since this has not been 
thoroughly investigated.
In brief, this study found that patients with SLE with 
an activated type I IFN system had impaired endothelial 
function and the patients with endothelial activation had 
increased platelet activation. Thus, we suggest that acti-
vation of platelets and platelet-endothelium interactions 
may contribute to impaired endothelial function and the 
development of CVD in SLE.
MateRIals and MetHOds
Patients and controls
Patients with SLE (n=148) as well as age-matched and 
sex-matched healthy controls (HCs, n=79) were recruited 
at the Department of Rheumatology, Skåne University 
Hospital, Lund, Sweden. An overview of the clinical char-
acteristics of the 148 patients with SLE and 79 healthy 
volunteers is presented in tables 1 and 2. Median disease 
duration of the patients with SLE was 11 years (range 
0–46). Disease activity in the patients with SLE was 
assessed using Systemic Lupus Erythematosus Disease 
Activity Index 2000 (SLEDAI-2K).26 Median SLEDAI-2K 
Score in the patients with SLE was 1.5 (range 0–18) and 
SLEDAI-2K Scores are demonstrated in table 2. All but 
two patients with SLE fulfilled at least four American 
College of Rheumatology (ACR) 1982 classification 
criteria for SLE.27 The last two patients fulfilled three 
ACR criteria, had a clinical SLE diagnosis with at least 
two organ manifestations characteristic of SLE, autoim-
mune phenomena and no other diagnosis that could 
better explain the symptoms. The median Systemic 
Lupus International Collaborating Clinics/ACR Damage 
Index (SLICC/ACR-DI) Score of the patients with SLE 
was 0 (range 0–8). The participants completed question-
naires concerning smoking, general health and medica-
tion. All subjects were examined by a rheumatologist at 
inclusion into the study. Traditional cardiovascular risk 
factors; age, gender, hypertension (systolic blood pres-
sure equal or higher than 140 mm Hg at the time point 
of blood sampling or hypertensive treatment due to 
high blood pressure) and plasma low density lipoprotein 
(LDL) cholesterol levels were analysed. History of cere-
brovascular incident (CVI), acute myocardial infarction 
(AMI) and deep venous thrombosis (DVT) or pulmonary 
embolism were verified in medical records and defined 
by SLICC/ACR-DI28 regardless of the time point of SLE 
diagnosis. Overnight fasting blood samples were drawn 
according to standard procedures at Skåne University 
Hospital, Lund, for determination of plasma lipids. Sera 
and EDTA plasma samples were stored at −80◦C. Comple-
ment and autoantibodies were measured by routine anal-
yses at the Division of Clinical Immunology and Transfu-
sion Medicine, Skåne University Hospital, Lund, Sweden.
Written informed consent was obtained from all 
participants.
IFn activity assay
Type I IFN activity was measured in three different ways:
1. Serum type I IFN activity was measured in patients 
with SLE as previously described.29 30 Briefly, WISH 
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Table 1 Demographics and distribution of traditional cardiovascular risk factors in patients with systemic lupus 
erythematosus (SLE) and healthy controls
Characteristics SLE Healthy controls p Value
Number 148 79
Female (%) 87 85 0.62
Age (years) median (range) 48 (20–82) 47 (18–81) 0.95
Current smoker (%) 21 9 0.02
BMI, mean and SD 25.48±4.94 23.45±3.05 <0.01
Hypertension* (%) 43 18 <0.01
P-LDL (mmol/L), mean and SD 3.06±0.95 3.16±0.87 0.34
P-EMP (EMP/mL), median (25,75) 2.71×105
(1.54, 7.70×105)
3.66×105
(1.89, 7.67×105)
0.46
P-sVCAM-1 (ng/mL), median (25,75) 783 (623, 965) 517 (444, 592) <0.01
RHI, median (25,75) 2.09 (1.70, 2.54) 2.16 (1.76, 2.64) 0.42
Platelet C1q dep (MFI ratio), median (25,75) 1.82 (1.59, 2.04) 1.61 (1.45, 1.79) <0.01
Platelet C4d dep (MFI ratio), median (25,75) 1.93 (1.56, 3.33) 1.44 (1.31, 1.65) <0.01
Serum IFN score (AU), median (25,75) 1.29 (1.05, 1.92) ND -
Acute myocardial infarction† (n) 10 0 -
Cerebrovascular insult† (n) 15 0 -
Deep venous thrombosis† (n) 24 0 -
Current medication
Glucocorticoids‡ (n) 98 0 -
Hydroxychloroquine (n) 105 0 -
Azathioprine (n) 32 0 -
Mycophenolate mofetil (n) 20 0 -
Methotrexate (n) 13 0 -
Intravenous immunoglobulins (n) 2 0 -
Non-steroidal anti-inflammatory drugs (n) 12 0 -
Acetylsalicylic acid (n) 44 0 -
Warfarin (n) 23 0 -
*Hypertension treatment due to high blood pressure or systolic blood pressure ≥140 mm Hg at the time point of blood sampling.
†Medical history.
‡Median daily dose=5 mg, range 1–30 mg.
(25,75), 25th and 75th centiles; AU, arbitrary unit; BMI, body mass index; P-EMP, plama endothelial microparticle; IFN, interferon; P-LDL, 
plasma low density lipoprotein; MFI, median fluorescence intensity; ND, not determined; Platelet C1q-C4d dep, deposition; RHI, Reactive 
Hyperaemia Index; P-sVCAM-1, plasma soluble vascular cell adhesion molecule-1. 
cells (CCL-25; American Type Culture Collection, 
Manassas, Virginia, USA) were cultured for 6 hours 
with patient serum after which lysis mixture (Panomics, 
Fremont, California, USA) was added. Cell lysates were 
analysed on a Luminex 100 (Luminex Corporation, 
Austin, Texas, USA) for mRNA expression of three 
housekeeping genes (GAPDH, PPIB, B2M) and six 
type I IFN-regulated genes (LY6E, MX1, OAS1, ISG15, 
IFIT1 and EIF2AK2) using the Quantigene Plex 2.0 
assay as described by the manufacturer (Panomics). 
The IFN score (indicating serum type I IFN activity) 
was calculated as the relative type I IFN-regulated 
genes expression in WISH cells exposed to SLE serum 
as compared with unstimulated WISH cells. The limit 
for a high serum type I IFN score was set to >2.0 as 
described earlier.29
2. Type I IFN signature in peripheral blood mononu-
clear cells (PBMCs) was measured in patients with 
SLE: PBMCs were isolated using Lymphoprep (Ax-
is-Shield) according to manufacturer’s protocol and 
type I IFN signature analysed with the Quantigene 
Plex 2.0 assay as described in the section above. PBMC 
type I IFN score was calculated as the mean expres-
sion of six type I IFN-regulated genes (LY6E, MX1, 
OAS1, ISG15, IFIT1 and EIF2AK2) normalised to 
three housekeeping genes (GAPDH, PPIB and B2M).
3. Quantification of the IFN- inducible protein galectin-
3-binding protein (G3BP) was performed using the 
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Table 2 Clinical characteristics of the 148 patients with 
systemic lupus erythematosus (SLE) included in the study 
according to the 1982 ACR classification criteria and 
disease activity measured by SLEDAI-2K Score at the time 
point of investigation
Characteristics SLE (n=148)
ACR criteria, median (range) 5 (3–10)
  Malar rash (%) 52
  Discoid rash (%) 20
  Photosensitivity (%) 56
  Oral ulcers (%) 24
  Arthritis (%) 78
  Serositis (%) 39
  Renal disease (%) 33
  Neurological disorders (%) 6
  Haematological manifestations (%) 55
  Leucopenia (%) 37
  Lymphopenia (%) 24
  Thrombocytopenia (%) 14
  Haemolytic anaemia (%) 2
  Immunology* (%) 69
  Anti-dsDNA antibodies (%) 59
  Anti-Smith antibodies (%) 10
  ANA (%) 98
SLEDAI-2K Score, median (range) 1.5 (0–18)
  Active disease SLEDAI≥4 29
  Organic brain syndrome (n) 1
  Lupus headache (n) 3
  Vasculitis (n) 1
  Arthritis (n) 15
  Kidney involvement (n)
  (urinary cast, haematuria, proteinuria or 
pyuria)
16
  Rash (n) 18
  Alopecia (n) 4
  Oral or nasal ulcers (n) 4
  Pleurisy (n) 2
  Low complement (C3 or C4) (n) 36
  Anti-dsDNA antibodies (n) 21
  Thrombocytopenia (n) 2
  Leucopenia (n) 9
*anti-dsDNA, anti-sm,  lupus erythematosus cells, false-positive 
Wasserman test.
ACR, American College of Rheumatology; ANA, antinuclear 
antibody.
Human 90K/Mac-2BP Platinum ELISA kit (BMS234, 
Bender MedSystem, Vienna, Austria).31 EDTA plasma 
samples, diluted 1:100 in sample diluent, were 
analysed in duplicate according to manufacturer’s 
instructions.
Biomarkers of endothelial dysfunction/activation
Plasma sVCAM-1 was analysed by ELISA according to the 
manufacturer’s protocol (R&D Systems Quantikine). The 
95th centile of the 79 healthy individuals determined the 
cut-off for the upper limit of normal sVCAM-1 and was 
set to 764 ng/mL. For detection of EMPs, flow cytom-
etry was performed directly on heparinised platelet-poor 
plasma.32 EMPs were labelled with murine monoclonal 
anti-CD146-fluorescein isothiocyanate (FITC) or the 
relevant isotype-matched control antibody, as previously 
described.32 33 The cut-off for upper limit of normal EMP 
was determined by the 95th centile of the healthy individ-
uals and was set to 1.98×106 EMP/mL.
Platelet activation
Platelet C1q and C4d deposition were analysed by flow 
cytometry as described previously.24 34 35 The upper limits 
of normal C1q and C4d deposition on platelets was deter-
mined by the 95th centile of HCs and was set to 2.40 and 
2.09 median fluorescence intensity ratio, respectively.
assessment of endothelial function
Endothelial function was determined using an EndoPAT 
2000 (Itamar Medical, Caesarea, Israel), which has been 
validated and used in previous studies.36–38 Subjects were 
examined according to the manufacturer’s protocol and 
as previously described.36 Changes in PWA in the finger 
artery during reactive hyperaemia were detected with a 
finger plethysmograph. A finger probe was placed on the 
index finger of the right hand and PWA was recorded with 
PAT at baseline, during suprasystolic cuff occlusion and 
during reactive hyperaemia. PWA was also recorded from 
the contralateral, left index finger not undergoing reac-
tive hyperaemia testing as a control. PAT measurements 
were analysed with a computerised automated algorithm 
(Itamar Medical, Caesarea, Israel). The cut-off for Reac-
tive Hyperaemia Index (RHI) was set to 1.67 according to 
manufacturer’s instructions (Itamar Medical).39
statistics
SPSS Statistics V.22 (IBM Corporation, Armonk, New York, 
USA) was used for all statistical analyses. For calculation of 
ORs and 95% CI, logistic regression analysis was applied. 
Results are presented unadjusted and after adjusting for 
CVD risk factors (age, gender, LDL plasma concentration, 
current smoking and hypertension) in all groups larger 
than n=30. In smaller groups (n=17) adjustment for age, 
gender and LDL plasma concentrations were made. Spear-
man’s rank correlation test was used to analyse correlations. 
Mann-Whitney U test and χ2 test were used when comparing 
values between groups shown in table 1. A p Value <0.05 was 
considered statistically significant.
Results
Patient characteristics
In total 148 patients with SLE and 79 HCs were included 
in the study and the clinical characteristics are demon-
strated in table 1.
 o
n
 7 M
ay 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2017-000508 on 25 O
ctober 2017. Downloaded from
 
5Tydén H, et al. RMD Open 2017;3:e000508. doi:10.1136/rmdopen-2017-000508
Lupus
Table 3 Correlations between endothelial activation and serum type I IFN activity in systemic lupus erythematosus (SLE)
Endothelial 
activation
sVCAM-1 high EMP high
OR CI 95% p Value OR CI 95% p Value
IFN activity* 1.68 1.15 to 2.47 <0.01 1.40 1.04 to 1.88 0.03
OR for indicators of endothelial activation; high sVCAM-1 and high EMP levels were calculated in patients with SLE in relation to serum type I 
IFN activity, adjusted for CVD risk factors. 
*adjusted for age, gender, smoking, hypertension, p-LDL concentration. Serum type I IFN activity was measured by a reporter gene 
expression assay (serum IFN score).
CVD, cardiovascular disease; EMP, endothelial microparticles; IFN, interferon; LDL, low density lipoprotein; sVCAM, soluble vascular cell 
adhesion molecule-1.
Table 4 Activated platelets in patients with systemic lupus erythematosus (SLE) with endothelial activation
Endothelial activation
Platelet/C4d high Platelet/C1q high
OR 95% CI p Value OR 95% CI p Value
sVCAM-1 high* 4.57 2.14 to 9.79 <0.01 4.10 1.09 to 15.38 0.04
sVCAM-1 high† 4.17 1.90 to 9.15 <0.01 4.15 1.07 to 16.18 0.04
EMP high* 3.64 1.16 to 11.38 0.03 2.16 0.51 to 9.16 0.30
EMP high† 3.11 0.97 to 9.98 0.056 2.05 0.47 to 8.91 0.34
OR for markers of platelet activation; platelet-C4d and platelet C1q deposition was calculated in patients with SLE with and without high 
sVCAM-1 and high EMP levels. Endothelial activation and platelet activation values are dichotomous. 
*Adjusted for age, gender, p-LDL concentration.
†Adjusted for age, gender, p-LDL and IFN activity.
EMP, endothelial microparticles; IFN, interferon; LDL, low density lipoprotein; platelet-C4d/platelet-C1q, platelet-C4d/C1q deposition; 
sVCAM-1, soluble vascular cell adhesion molecule-1.
Patients with sle with activation of the type I IFn system 
have activated endothelium
Activation of the type I IFN system has been suggested to 
contribute to endothelial dysfunction. This study there-
fore set out to investigate if patients with SLE with type I 
IFN activity have signs of endothelial dysfunction. Three 
different assays to measure type I IFN activity were used, 
serum type I IFN activity, IFN signature in PBMCs and 
plasma levels of G3BP. Using Spearman's rank correla-
tion test, the data showed that there was a good corre-
lation between all assays (serum type I IFN activity and 
IFN signature in PBMCs (r=0.65, p<0.01), serum type I 
IFN activity and plasma levels of G3BP (r=0.54, p<0.01), 
and IFN signature in PBMCs and plasma G3BP protein 
levels (r=0.48, p<0.01). Serum type I IFN scores in the 
patients with SLE are presented in table 1. Median 
value for serum type I IFN score was 1.29 arbitrary units 
(AU) in patients with SLE. Patients with SLE had signifi-
cantly higher plasma levels of G3BP compared with HCs 
(median 3345 ng/mL vs 2738 ng/mL, p<0.01). The 
median PBMC score in patients with SLE was 0.10 AU. As 
similar results were found for these three different assays, 
the serum type I IFN activity was used for future analyses.
In the study cohort of patients with SLE, activation of 
the type I IFN system was demonstrated and was associ-
ated with endothelial activation. The endothelial activa-
tion was measured as high sVCAM-1 and high EMPs. This 
association remained after adjusting for CVD risk factors 
(table 3).
Patients with sle with endothelial activation have increased 
platelet activation
As platelets have been implicated in the development of 
CVD in patients with SLE, the association between platelet 
activation and endothelial activation in patients with SLE 
was examined. Both high serum levels of sVCAM-1 and 
EMPs, reflecting endothelial activation, were associated 
with activated platelets measured as high platelet C4d 
deposition (table 4). High levels of sVCAM-1, but not 
high EMP, was associated with platelet activation meas-
ured as high platelet C1q deposition (table 4). Since the 
smallest group consisted of 17 individuals, adjustment 
for three instead of five CVD risk factors was made. In 
order to investigate the independent effect of platelet 
activation on endothelial dysfunction, the data were also 
adjusted for serum IFN activity (table 4). After adjusting 
for IFN activation, the association between sVCAM-1, but 
not EMP, and platelet activation remained, possibly due 
to a relatively small sample size. No association between 
platelet activation and serum type I IFN activity was seen.
Patients with sle with type I IFn activity have signs of 
vascular dysfunction measured by endopPat
As we had seen that patients with SLE with type I IFN 
activity had signs of endothelial activation, the patients 
were tested to determine if these patients had detectable 
signs of vascular dysfunction measured by EndoPAT.
Patients with SLE with high serum type I IFN activity, 
more often had a pathological RHI (<1.67) compared 
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Table 5 Endothelial dysfunction in patients with systemic 
lupus erythematosus (SLE) with increased type I IFN activity
Tested groups
RHI
OR 95% CI p Value
SLE (n=142) versus 
HCs (n=77) 1.30 0.66 to 2.58 0.45
SLE (n=142) versus 
HCs (n=77)* 1.31 0.61 to 2.80 0.49
SLE IFN+ (n=31) 
versus HCs (n=77) 2.61 1.04 to 6.53 0.04
SLE IFN+ (n=31) 
versus HCs (n=77)* 3.33 1.003 to 11.06 <0.05
OR for Reactive Hyperaemia Index (RHI) were calculated in 
patients with SLE and HCs, unadjusted and adjusted for CVD risk 
factors. Subgroup analysis in patients with SLE with (IFN+) and 
without ongoing serum type I IFN activity were performed.
*adjusted for age, gender, hypertension, smoking, p-LDL 
concentration.
CVD, cardiovascular disease; HCs, healthy controls; IFN, 
interferon; LDL, low density lipoprotein.
with HCs (OR 2.61, 95% CI 1.04 to 6.53, p=0.04) and 
this association remained statistically significant after 
adjusting for CVD risk factors (age, gender, plasma LDL 
(p-LDL) concentration, smoking and hypertension) 
(table 5). No difference in RHI was seen when comparing 
all patients with SLE and HCs (table 5).
These data indicate that vascular dysfunction could be 
detected by EndoPAT in patients with SLE with high type 
I IFN activity.
High levels of sVCaM-1 are associated with previous CVd 
comorbidity
In total, 43 patients with SLE had a history of CVD events 
(CVI, n=15), (AMI, n=10) or (DVT, n=24). High sVCAM-1 
levels were associated with previous CVI in patients with 
SLE (OR 3.77, 95% CI 1.02 to 13.96, p<0.05) also after 
adjusting for CVD risk factors (OR 4.32, 95% CI 1.05 to 
17.86, p=0.04).
None of the other tested parameters, type I IFN activity, 
levels of EMP, nor RHI, were associated with a history of 
CVD.
no correlation identified between the different markers of 
endothelial dysfunction
The data were interrogated to determine if RHI, sVCAM-1 
and EMP were related. No correlation was found 
between RHI, sVCAM-1 and EMP in either patients with 
SLE or HCs. Furthermore, no direct correlation between 
sVCAM-1 and EMP in SLE or HCs could be found. Thus, 
the data derived from measurements of these variables 
may represent different aspects of endothelial dysfunc-
tion and endothelial activation.
dIsCussIOn
In this study, a connection between the type I IFN system 
and endothelial function could be demonstrated since 
endothelial activation, measured as high sVCAM-1 and 
elevated EMPs was seen in patients with SLE with acti-
vated type I IFN system. In addition, we found impaired 
endothelial function, assessed with EndoPAT, in patients 
with SLE with high type I IFN activity. Furthermore, we 
show increased platelet activation in patients with SLE 
with endothelial activation. These observations support 
the theory that increased type I IFN activity affects 
endothelial function.
Type I IFNs have modulatory effects on the immune 
system and promote autoimmunity in SLE.19 Furthermore, 
type I IFNs are suggested to negatively affect endothelial 
function and to increase prevalence of atherosclerosis.5 40 
This suggests that activation of type I IFN may have direct 
impact on the cardiovascular risk for patients with SLE. 
In our study, it was demonstrated that patients with SLE 
with type I IFN activity have altered vascular homoeostasis, 
assessed by decreased RHI and increased levels of sVCAM-1 
and EMPs. Thus, our data, in concordance with previous 
findings, suggest that patients with SLE with type I IFN 
activity are at highest risk to develop CVD.
Perturbation of vascular homoeostasis can be measured 
with biomarkers, including sVCAM-1 and EMPs. Further-
more, endothelial function of the peripheral circulation 
can be assessed by non-invasive methods, such as FMD 
and by a finger plethysmograph, EndoPAT. EMPs and 
sVCAM-1 have both been described as markers of endo-
thelial dysfunction and endothelial activation10 11 13–15 41 
and are potential surrogate markers for FMD and RHI. 
However, reports of correlations between EMP, sVCAM-1 
and RHI or FMD have been contradictory.13 42–44 In this 
study, no correlation was seen between the sVCAM-1, EMP 
and RHI values. Although all these markers are related 
to endothelial dysfunction, they may represent different 
parts of disease processes occurring in sequence, rather 
than concurrently. The different markers may be partly 
induced by different stimuli, including type I IFNs, and 
this may explain the lack of correlation. Further studies 
are required to understand the relations between the 
different markers of endothelial dysfunction and activa-
tion and their corresponding contribution to end-term 
damage, for example, atherosclerosis.
There is growing evidence that platelets may play a part 
in the pathogenesis of SLE,7 in addition to their role in 
development of atherosclerosis.6 8 In vitro studies suggest 
that platelets can affect EPCs to differentiate either to 
endothelial cells or to macrophages or foam cells, and 
thereby contribute either to vascular repair or injury.8 25 
We have previously shown increased platelet activation in 
SLE and demonstrated platelets with an IFN signature in 
patients with SLE with CVD.24 34 In SLE, platelets have 
also been shown to stimulate plasmacytoid dendritic cells 
to produce IFN, through CD40–CD154 interactions, with 
possible effects on the endothelium.7 In a recent study, 
it was demonstrated that activated platelets in SLE can 
promote endothelial cell activation by an IL-1β-depen-
dent pathway.45 Injured endothelium, on the other hand, 
could affect the platelets and activate them,8 leading to 
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a vicious circle of endothelium-platelet interaction with 
increased cardiovascular risk.
In the current study, we made the novel observation that 
platelet activation was related to endothelial activation in 
patients with SLE. Platelet activation was associated with 
both elevated serum sVCAM-1 concentration and high 
EMP levels. This is consistent with the hypothesis that 
interactions between activated platelets and activated 
endothelium occurs and that platelet activation might 
contribute to endothelial dysfunction. No direct correla-
tion between platelet activation and type I IFN activity 
was established, suggesting that platelet activation might 
be a result of the activated or dysfunctional endothelium 
in the patients. Indeed, in patients with stable coronary 
heart disease platelet activation correlates to endothelial 
dysfunction.46 Nevertheless, further studies are needed 
to understand the mechanistic relation between type I 
IFN activity and platelet activation.
As mentioned above, there are some limitations of our 
study. The patients in our study are treated with immu-
nosuppressive medication, including steroids, at the time 
point of blood sampling and investigation and this may 
affect the results. It is well known that type I IFN signal-
ling is affected by glucocorticoid treatment.47 In addition, 
the relatively few numbers of patients in the different 
subgroups may result in lack of significance when calcu-
lating associations.
Although most of the patients in our cross-sectionally 
studied cohort had relatively low disease activity, they still 
had signs of endothelial and platelet activation that could 
contribute to increased CVD risk. Therefore, we believe 
it is important to further investigate the mechanisms 
behind endothelial and platelet activation including in 
patients with SLE also with low disease activity.
In conclusion, patients with SLE with an activated 
type I IFN system have impaired endothelial function, 
connecting central pathogenic processes in SLE with 
endothelial dysfunction and CVD. We hypothesise that 
type I IFN-injured endothelium leading to platelet acti-
vation may play a role in the development of CVD in 
SLE. Our results suggest that assessing RHI, type I IFN 
signature and markers of platelet activation, in addition 
to traditional CVD risk factors, may be important when 
evaluating CVD risk in the individual patient.
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